West Pharmaceutical Services, Inc. WST

Company Overview

West Pharmaceutical Services, Inc. is a U.S.-based medical technology and pharmaceutical packaging company that develops and manufactures injectable drug administration and containment systems for the biopharmaceutical, pharmaceutical, and healthcare industries. The company operates primarily in the drug delivery, injectable packaging, and containment solutions markets, supplying components and systems used in biologics, vaccines, generics, and specialty pharmaceuticals. Its core revenue drivers include elastomer-based stoppers and seals, advanced delivery systems for injectable medicines, and high-value containment solutions used in sensitive biologic therapies. West also provides contract manufacturing, analytical testing, and device assembly services to pharmaceutical customers.

The company traces its origins to 1923, when Herman O. West founded the business to manufacture rubber components for pharmaceutical packaging. Over time, West evolved from a packaging supplier into a global provider of integrated drug containment and delivery technologies. The company has expanded through internal product development and acquisitions, particularly in advanced injectable systems and self-administration technologies. West is widely recognized for its strong position in high-quality elastomer components and its long-standing relationships with major global pharmaceutical and biotechnology companies.

Business Operations

West organizes its operations primarily into two business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment generates most of the company’s revenue and includes elastomer components, vial containment systems, self-injection devices, cartridge components, syringe systems, and advanced delivery technologies marketed under various branded platforms. The Contract-Manufactured Products segment provides manufacturing, assembly, and packaging services for medical devices, diagnostic products, and pharmaceutical delivery systems on behalf of healthcare customers. Revenue is generated through long-term pharmaceutical supply relationships, device commercialization support, and sales of high-performance containment systems used in injectable therapies.

West operates manufacturing, research, and distribution facilities across North America, Europe, Asia-Pacific, and Latin America. The company controls specialized elastomer formulation technologies, coating technologies, and sterile manufacturing capabilities that support highly regulated pharmaceutical applications. Important subsidiaries and operational entities include West Pharmaceutical Services Deutschland GmbH, West Pharmaceutical Services Singapore Pte. Ltd., and West Pharmaceutical Services, Inc. international affiliates. The company has also maintained collaborative relationships with pharmaceutical and biotechnology firms focused on biologics, vaccine production, and self-administration systems.

Strategic Position & Investments

West’s strategic direction has focused on expanding higher-margin, high-value products tied to biologics, injectable therapies, and self-administered drug delivery systems. The company has invested heavily in advanced containment technologies designed to reduce contamination risk and improve compatibility with sensitive biologic drugs. Growth initiatives have included manufacturing capacity expansions in Europe, the United States, and Asia to support rising demand for injectable medicines and GLP-1-related therapies. West has also emphasized digital manufacturing processes, quality automation, and integrated device solutions to strengthen relationships with large pharmaceutical customers.

The company has pursued acquisitions and strategic investments to broaden its technology portfolio and manufacturing capabilities. Notable acquisitions include NovaPure, Daikyo Seiko, Ltd. collaborations and technology arrangements, and the acquisition of Medimop Medical Projects Ltd., which strengthened West’s self-injection and delivery device offerings. West has increasingly positioned itself within high-growth sectors such as biologics, cell and gene therapies, and advanced injectable therapeutics. Public filings and investor materials indicate continued focus on high-value products, operational efficiency, and capacity investments aligned with long-term pharmaceutical demand trends.

Geographic Footprint

West Pharmaceutical Services is headquartered in Exton, Pennsylvania, United States, and maintains a substantial global manufacturing and commercial footprint. The company operates across North America, Europe, Asia-Pacific, and Latin America, serving multinational pharmaceutical and biotechnology companies in developed and emerging healthcare markets. Major operational locations include facilities in the United States, Ireland, Germany, France, Singapore, China, Japan, and Brazil.

The company’s international presence supports global pharmaceutical supply chains and enables localized production for regulated healthcare markets. West has established manufacturing and technical service capabilities near major pharmaceutical hubs in Europe and Asia-Pacific, allowing the company to support vaccine production, biologics manufacturing, and injectable drug commercialization on a global scale. Its broad geographic reach also helps diversify customer exposure across large pharmaceutical companies, generics manufacturers, and emerging biotechnology firms.

Leadership & Governance

West Pharmaceutical Services operates under a leadership structure focused on pharmaceutical innovation, operational quality, and long-term customer partnerships. The company’s governance model reflects its role as a regulated healthcare supplier serving global pharmaceutical manufacturers. Strategic priorities communicated through public filings and investor communications have emphasized innovation in injectable drug delivery, manufacturing excellence, and disciplined capital allocation.

Key executives include:

• Eric M. Green – President and Chief Executive Officer
• Bernard Birkett – Senior Vice President and Chief Financial Officer
• Silji Abraham – Senior Vice President, Chief Technology Officer
• Amin Motamed – Senior Vice President, Chief Commercial Officer
• Jennifer L. Schneiders – Senior Vice President, Chief Human Resources Officer
• William J. Federici – Senior Vice President, General Counsel and Secretary

The company’s leadership strategy has consistently emphasized expansion in high-value pharmaceutical containment systems, strengthening global manufacturing capacity, and supporting complex injectable therapies through technical partnerships with pharmaceutical and biotechnology customers.